Terence Ketter

Clinical Focus

• Psychiatry

Administrative Appointments

• Chief, Bipolar Disorders Clinic (1995 - 2004)

Honors and Awards

• Distinguished Fellow, American Psychiatric Association (2006)
• Independent Investigator Award, National Alliance for Research in Schizophrenia and Depression (2003-2005)
• Outstanding Faculty Physician Award, Vaden Health Center, Stanford University (2002)
• Independent Investigator Award, National Alliance for Research in Schizophrenia and Depression (1999-2001)
• Independent Investigator Award, Stanley Foundation Research Award Program (1996-2000)

Professional Education

Postdoctoral Advisees

Shefali Srivastava

Graduate & Fellowship Program Affiliations

• Neurosciences
• Psychiatry and Behavioral Science

Web Site Links

• Stanford Bipolar DIosrders Clinic

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

Dr. Ketter has done extensive research into the etiology, phenomenology, and treatment of bipolar disorder. His etiologic research has focused on the use of brain imaging methods such as magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and positron emission tomography (PET) to better understand the neurobiology of mood disorders and to explore the possibility of using these techniques to more effectively target treatments for patients with bipolar disorder. His phenomenologic research has focused on the development and course of bipolar disorder in late adolescence and young adulthood, particularly in college students, and links between creativity, temperament, and mood disorders. His research into treatment has involved clinical trials of novel medications and combinations of medications in the treatment of bipolar disorder, with an emphasis on the use of anticonvulsants.

Clinical Trials

• Short Term Rescue Study of Olanzapine Recruiting

Publications

• Insulin resistance and hyperlipidemia in women with bipolar disorder. Stemmle PG, Kenna HA, Wang PW, Hill SJ, Ketter TA, Rasgon NL. J Psychiatr Res. 2009; 43 (3): 341-3
• Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ. J Psychiatr Res. 2009
• Decreased prefrontal, anterior cingulate, insula, and ventral striatal metabolism in medication-free depressed outpatients with bipolar disorder. Brooks JO, Wang PW, Bonner JC, Rosen AC, Hoblyn JC, Hill SJ, Ketter TA. J Psychiatr Res. 2009; 43 (3): 181-8
• Treating bipolar disorder: monotherapy versus combination therapy. Ketter TA, J Clin Psychiatry. 2009; 70 (2): e42
• Divalproex extended-release in acute bipolar II depression. Wang PW, Nowakowska C, Chandler RA, Hill SJ, Nam JY, Culver JL, Keller KL, Ketter TA. J Affect Disord. 2009